Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Key Inclusion Criteria:~* Males and females, 18 to 70 years of age~* Hepatitis C virus (HCV) genotype 1a or 1b~* HCV-treatment naive~* HCV RNA \>10,000 IU/mL at screening~* HIV-1 infection (approximately 250 patients receiving highly active antiretroviral therapy \[HAART\], up to 50 patients not receiving HAART)~* For patients receiving HAART, HIV RNA must be below \<40 copies/mL at screening and must be \<400 copies/ml for at least 6 months prior to screening~Key Exclusion Criteria:~* Patients receiving HAART who first initiated antiretroviral therapy within the last 6 months of Day 1~* Patients receiving HAART who have changed their antiretroviral regimen due to safety or efficacy associated to HIV treatment within the last 3 months prior to Day 1. However, if changes are required to a patient's HAART regimen to meet the requirements of the protocol, these changes are allowed at the screening visit. The patient should wait a minimum of 1 month prior to Day 1 after a repeat of HIV viral load has been confirmed, \<40 copies/ mL~* Use of prohibited HAART regimens within 1 month of Day 1 and throughout the treatment period of the trial (patients receiving HAART who have changed their antiretroviral regimen to initiate any HCV treatment within 6 weeks prior to Day 1)~* Laboratory values:~  1. Neutrophil count \<1500 cells/μL (\<1200 cells/ μL for Blacks)~ 2. Platelet count \<90,000 cells/μL~ 3. Hemoglobin ≤12 g/dL for females, hemoglobin ≤13 g/dL for males~ 4. Total bilirubin ≥34 μmol/L (or ≥2 mg/dL) unless a patient has a documented history of Gilbert's disease or antiretroviral regimen contains atazanavir~ 5. Alanine aminotransferase ≥5\*upper limit of normal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Daclatsvir + Ribavirin + PEG-Interferon alfa-2a (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).